[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637612":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":49,"collaborators":20,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Beni-Suef University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"control","EXPERIMENTAL","patients will take no intervention",[13],"Combination Product: diosmin\u002Fhesperdin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"COMBINATION_PRODUCT","diosmin\u002Fhesperdin","combination of Diosmin and Hesperidin",[9],null,[22],{"name":23,"affiliation":24,"role":25},"marwa mohsen","clinical pharmacy department, Beni Suef University","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"marwa mohsen, PhD","CONTACT","01202203223","marwa.mohsen@pharm.bsu.edu.eg",[33],{"facility":34,"status":35,"city":36,"state":20,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Faculty of Medicine","RECRUITING","Banī Suwayf","0000","Egypt","EG",{"type":41,"coordinates":42},"Point",[43,44],31.09785,29.07441,{"lat":44,"lon":43},[47],{"name":48,"role":29,"phone":20,"phoneExt":20,"email":20},"beni suef university",{"type":25,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Hasnaa Osama","lecturer","100637612","phase-4-effect-of-diosminhesperidin-combination-on-platinum-compounds-induced-nephropathy-in-cancer-patients-100637612",false,"NCT07598214","Effect of Diosmin\u002FHesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients","Evaluation of the Effect of Diosmin\u002FHesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients: A Randomized Controlled Trial","Dios\u002FHes-PT","Inclusion Criteria:\n\n* Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy.\n\nExclusion Criteria:\n\n* -History of allergic reactions attributed to drugs in the study.\n* Pregnant women.\n* Life expectancy less than 6 months\n* Inability or unwillingness to comply with research protocols.\n* Cancer patients with impaired renal function (creatinine clearance \\\u003C 50 mL\u002Fmin)\n* Preexisting hearing loss.\n* Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.","ALL","18 Years","75 Years",{"count":64,"type":65},100,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","The current study aims to investigate the protective properties of diosmin\u002Fhesperidin on cisplatin-induced nephrotoxicity.",[71],"Cancer Patients","2026-05-17",{"date":74,"type":75},"2026-05-20","ACTUAL",{"date":77,"type":75},"2025-02-03",{"date":79,"type":65},"2026-12-03",{"name":5,"class":6},1]